Which medications in the drug class Phosphodiesterase (type 5) Enzyme Inhibitor are used in the treatment of Mixed Connective-Tissue Disease?

Updated: Oct 01, 2018
  • Author: Eric L Greidinger, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Phosphodiesterase (type 5) Enzyme Inhibitor

Phosphodiesterase inhibitors can ameliorate symptoms of pulmonary hypertension and Raynaud phenomenon in patients with MCTD. These agents may not be as durable as other drug classes in improving pulmonary hypertension, but the adverse-effect profile of phosphodiesterase inhibitors is often more favorable than prostaglandin or anti-endothelin therapies.


Promotes selective smooth-muscle relaxation in lung vasculature, possibly by inhibiting phosphodiesterase type 5 (PDE-5). This reduces blood pressure in pulmonary arteries and increase in cardiac output.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!